uniQure N.V. Sublease Income
uniQure N.V. (QURE) reported Sublease Income of $1.54 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2026-03-02
- uniQure N.V. sublease income for the quarter ending 2020-12-31 was $225.00K, a 13.79% decline year-over-year.
- uniQure N.V. sublease income for the quarter ending 2020-09-30 was $222.00K, a 14.62% decline year-over-year.
- uniQure N.V. sublease income for the quarter ending 2020-06-30 was $209.00K, a 20.83% decline year-over-year.
- uniQure N.V. sublease income for the quarter ending 2020-03-31 was $248.00K, a 7.46% decline year-over-year.
- uniQure N.V. sublease income for fiscal 2025 was $1.54M, a 32.53% increase from fiscal 2024.
- uniQure N.V. sublease income for fiscal 2024 was $1.16M, a 21.42% increase from fiscal 2023.
- uniQure N.V. sublease income for fiscal 2023 was $957.00K, a 12.72% increase from fiscal 2022.
- uniQure N.V. sublease income for fiscal 2022 was $849.00K, a 6.39% decline from fiscal 2021.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.54M 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $1.16M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $957.00K 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $849.00K 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $907.00K 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $447.00K derived: sum of 2 quarters · filed 2023-02-27 | $656.00K derived: sum of 3 quarters · filed 2023-02-27 | $904.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $222.00K 10-Q · filed 2020-10-27 | $431.00K derived: sum of 2 quarters · filed 2020-10-27 | $679.00K 10-Q · filed 2020-10-27 | $940.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $209.00K 10-Q · filed 2020-07-30 | $457.00K 10-Q · filed 2020-07-30 | $718.00K derived: sum of 3 quarters · filed 2022-02-25 | $978.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $248.00K 10-Q · filed 2020-04-29 | $509.00K derived: sum of 2 quarters · filed 2022-02-25 | $769.00K derived: sum of 3 quarters · filed 2022-02-25 | $1.03M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $521.00K derived: sum of 2 quarters · filed 2022-02-25 | $785.00K derived: sum of 3 quarters · filed 2022-02-25 | $1.05M 10-K · filed 2022-02-25 |
| 2019-09-30 | $260.00K 10-Q · filed 2020-10-27 | $524.00K derived: sum of 2 quarters · filed 2020-10-27 | $792.00K 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $264.00K 10-Q · filed 2020-07-30 | $532.00K 10-Q · filed 2020-07-30 | ||
| 2019-03-31 | $268.00K 10-Q · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |